148 related articles for article (PubMed ID: 36580307)
21. Optimal Timing of Surgical Resection After Radiation in Locally Advanced Rectal Adenocarcinoma: An Analysis of the National Cancer Database.
Huntington CR; Boselli D; Symanowski J; Hill JS; Crimaldi A; Salo JC
Ann Surg Oncol; 2016 Mar; 23(3):877-87. PubMed ID: 26514119
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy.
Kennecke HF; Bahnson HT; Lin B; O'Rourke C; Kaplan J; Pham H; Suen A; Simianu VV
JAMA Oncol; 2022 Oct; 8(10):1466-1470. PubMed ID: 35980607
[TBL] [Abstract][Full Text] [Related]
23. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
[TBL] [Abstract][Full Text] [Related]
24. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
25. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
[TBL] [Abstract][Full Text] [Related]
26. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
27. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
28. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in rectal cancer patients-a propensity score matched analysis of the National Cancer Database.
Horesh N; Emile SH; Freund MR; Garoufalia Z; Gefen R; Nagarajan A; Wexner SD
Int J Colorectal Dis; 2023 Dec; 39(1):8. PubMed ID: 38133666
[TBL] [Abstract][Full Text] [Related]
30. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.
Park JW; Kang SB; Hao J; Lim SB; Choi HS; Kim DW; Chang HJ; Kim DY; Jung KH; Kim TY; Kang GH; Chie EK; Kim SY; Sohn DK; Kim JS; Lee HS; Kim JH; Jeong SY; Oh JH
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):569-577. PubMed ID: 33894918
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
[TBL] [Abstract][Full Text] [Related]
32. Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project.
Pellino G; Alós R; Biondo S; Codina-Cazador A; Enríquez-Navascues JM; Espín-Basany E; Roig-Vila JV; Cervantes A; García-Granero E;
Eur J Surg Oncol; 2021 Feb; 47(2):276-284. PubMed ID: 32950316
[TBL] [Abstract][Full Text] [Related]
33. Temporal Trends in Treatment and Outcomes of Endometrial Carcinoma in the United States, 2005-2020.
Adekanmbi V; Guo F; Hsu CD; Gao D; Polychronopoulou E; Sokale I; Kuo YF; Berenson AB
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610960
[TBL] [Abstract][Full Text] [Related]
34. Robotic-assisted surgery for rectal adenocarcinoma: short-term and midterm outcomes from 200 consecutive cases at a single institution.
Hara M; Sng K; Yoo BE; Shin JW; Lee DW; Kim SH
Dis Colon Rectum; 2014 May; 57(5):570-7. PubMed ID: 24819096
[TBL] [Abstract][Full Text] [Related]
35. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
[TBL] [Abstract][Full Text] [Related]
36. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
37. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
39. Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study.
Peltrini R; Castiglioni S; Imperatore N; Ortenzi M; Rega D; Romeo V; Caracino V; Liberatore E; Basti M; Santoro E; Bracale U; Delrio P; Mucilli F; Guerrieri M; Corcione F
Tech Coloproctol; 2023 Jan; 27(1):53-61. PubMed ID: 36239872
[TBL] [Abstract][Full Text] [Related]
40. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
